AVITA Medical announced it has submitted its response to the FDA for additional information requested in connection to its premarket approval, or PMA, supplement for Recell Go. This submission resumes the substantive interactive review process under the breakthrough devices program. The response addresses various questions and incorporates data from in-house testing to support the PMA supplement and fulfil the additional information request, which we received in October of 2023. Upon receipt by the FDA, the application of the PMA supplement resumes its 180-day real time review, with 90 days remaining in the review period. Therefore, we expect FDA approval on May 30, positioning us for a product launch on May 31.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RCEL:
- AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
- AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference
- AVITA Medical to Host Investor Webinar Briefing
- Avita Medical price target raised to $26 from $20 at BTIG
- Avita Medical price target raised to $25 from $22 at Cantor Fitzgerald